TrialGlobe

China research layer

Clinical trials in China

A dedicated view of active obesity and GLP-1 studies with research locations in mainland China, linked back to their public registry records.

326active studies
170recruiting now
145cities represented
139lead sponsors
China coverage here comes from ClinicalTrials.gov records with a China location. PharmaData's separate archive architecture is designed to add ChiCTR and NMPA/CDE provenance when lawful exports are available.

Active China studies

Top cities: Beijing, Shanghai, Nanjing, Hefei, Guangzhou, Jinan, Chongqing, Hangzhou.

Prehypertension, Borderline DyslipidemiaCondition
Smartwatch-Based Multi-Faceted Behavioral Intervention Model Led by Exercise and Dietary Interventions, Supported by Primary Medical Staff, Along with the Distribution of Health Education Manuals, Face-to-face health education sessionsTreatment
China3 locations
Beijing Anzhen HospitalSponsor
Updated 2026-05-14 · NCT07372729See eligibility →
Recruiting nowNot applicable

Probiotic Intervention on Body Weight

Obesity, HomeostasisCondition
General lifestyle and nutritional education, Energy-restricted nutritional and lifestyle interventionTreatment
China1 locations
Chinese Academy of SciencesSponsor
Updated 2026-03-17 · NCT06989177See eligibility →
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyCondition
HRS9531, PlaceboTreatment
China1 locations
Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor
Updated 2026-01-26 · NCT06994650See eligibility →